Citations

Showing 10 of 108135 citations.

Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities
Syrjanen, Jeremy A. , Campbell, Michelle R. , Algeciras‐Schimnich, Alicia , Vemuri, Prashanthi , Graff‐Radford, Jonathan, Bu, Guojun , Jack, Clifford R. , Petersen, Ronald C. , Algeciras-Schimnich, Alicia , Jack, Clifford R , Vemuri, Prashanthi , Bu, Guojun , Graff‐Radford, Jonathan , Machulda, Mary M. , Knopman, David S. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | September 27, 2021 | Volume: 18 | Issue: 6 | Pages: 1128-1140

10.1002/alz.12466 | PMID 34569696 Get It

AbstractIntroductionBlood‐based biomarkers of amyloid pathology and neurodegeneration are entering clinical use. It is critical to understand what factors affect the levels of these markers.MethodsPlasma markers (Aβ42, Aβ40, NfL, T‐tau, Aβ42/40 ratio) were measured on the Quanterix Simoa HD‐1 analyzer for 996 Mayo Clinic Study of Aging (MCSA) participants, aged 51 to 95 years. All other data were collected during in‐person MCSA visits or abstracted from the medical record.ResultsAmong cognitively unimpaired (CU) participants, all plasma markers correlated with age. Linear regression models revealed multiple relationships. For example, higher Charlson Comorbidity Index and chronic kidney disease were associated with higher levels of all biomarkers. Some relationships differed between mild cognitive impairment and dementia participants.DiscussionMultiple variables affect plasma biomarkers of amyloid pathology and neurodegeneration among CU in the general population. Incorporating this information is critical for accurate interpretation of the biomarker levels and for the development of reference ranges.
Post-vaccination COVID Toes (Chilblains) Exacerbated by Rituximab Infusion Suggests Interferon Activation as Mechanism
Qiao, Jana, Dan, Yongwook, Wolf, Michael E. , Zoccoli, Christina, Demetriou, Theodore J, Lennon, Robert P. , Wolf, Michael E

Mayo Clinic

Military Medicine | September 27, 2021 | Volume: 187 | Issue: Special Issue_13 | Pages: e1563-e1565

10.1093/milmed/usab314 | PMID 34570195 Get It

ABSTRACT Coronavirus disease (COVID) toes are pernio-like skin lesions associated with severe acute respiratory syndrome coronavirus 2. We observed pernio-like skin findings presenting after a Pfizer BioNTech vaccine, which significantly worsened after an infusion of rituximab. This suggests that the mechanism for COVID toes is interferon activation. Military providers may avoid unnecessary referrals for this self-limiting condition by anticipating this adverse effect.
No Difference in Neck Pain or Health-Related Quality Measures Between Patients With or Without Degenerative Cervical Spondylolisthesis
Kaye, I. David , Sebastian, Arjun S. , Wagner, Scott C. , Semenza, Nicholas C. , Bowles, Daniel R. , Schroeder, Gregory D. , Kepler, Chris K., Woods, Barret I., Rihn, Jeff, Anderson, David Greg, Hilibrand, Alan S. , Kepler, Christopher K. , Kaye, Ian David , Semenza, Nicholas , Radcliff, Kris E. , Kurd, Mark F. , Vaccaro, Alexander R.

Mayo Clinic

Global Spine Journal | September 27, 2021 | Volume: 13 | Issue: 6 | Pages: 1641-1645

10.1177/21925682211046906 | PMID 34570993 Get It

Study Design This study is a retrospective case control. Objectives This study aims to determine whether cervical degenerative spondylolisthesis (DS) is associated with increased baseline neck/arm pain and inferior health quality states compared to a similar population without DS. Methods Patient demographics, pre-operative radiographs, and baseline PROMs were reviewed for 315 patients undergoing anterior cervical decompression and fusion (ACDF) with at least 1 year of follow-up. Patients were categorized based on the presence (S) or absence of a spondylolisthesis (NS). Statistically significant variables were further explored using multiple linear regression analysis. Results 49/242 (20%) patients were diagnosed with DS, most commonly at the C4–5 level (27/49). The S group was significantly older than the NS group (58.0 ± 10.7 vs 51.9 ± 9.81, P = .001), but otherwise, no demographic differences were identified. Although a higher degree of C2 slope was found among the S cohort (22.5 ± 8.63 vs 19.8 ± 7.78, P = .044), no differences were identified in terms of preoperative visual analogue scale (VAS) neck pain or NDI. In the univariate analysis, the NS group had significantly increased VAS arm pain relative to the S group (4.93 ± 3.16 vs 3.86 ± 3.30, P = .045), which was no longer significant in the multivariate analysis. Conclusions Although previous reports have suggested an association between cervical DS and neck pain, we could not associate the presence of DS with increased baseline neck or arm pain. Instead, DS appears to be a relatively frequent (20% in this series) age-related condition reflecting radiographic, rather than necessarily clinical, disease.
Validating a Computable Phenotype for Nephrotic Syndrome in Children and Adults Using PCORnet Data
Oliverio, Andrea L. , Marchel, Dorota, Troost, Jonathan P. , Ayoub, Isabelle , Almaani, Salem , Greco, Jessica, Tran, Cheryl L., Denburg, Michelle R., Matheny, Michael E. , Dorn, Chad, Massengill, Susan F. , Desmond, Hailey, Greco, Jessica , Matheny, Michael , Gipson, Debbie S , Oliverio, Andrea L. , Marchel, Dorota, Troost, Jonathan P. , Ayoub, Isabelle , Almaani, Salem , Tran, Cheryl L., Denburg, Michelle R., Dorn, Chad, Massengill, Susan F. , Desmond, Hailey, Mariani, Laura H.

Mayo Clinic

Kidney360 | September 27, 2021 | Volume: 2 | Issue: 12 | Pages: 1979-1986

10.34067/kid.0002892021 | PMID 35419531 Get It

Key Points A computable phenotype combines routinely collected data elements from the EHR with logic elements to identify a condition of interest. This validated computable phenotype has strong classification characteristics to identify individuals with primary nephrotic syndrome. This computable phenotype for primary nephrotic syndrome can facilitate future research of these rare diseases. Background Primary nephrotic syndromes are rare diseases which can impede adequate sample size for observational patient-oriented research and clinical trial enrollment. A computable phenotype may be powerful in identifying patients with these diseases for research across multiple institutions. Methods A comprehensive algorithm of inclusion and exclusion ICD-9 and ICD-10 codes to identify patients with primary nephrotic syndrome was developed. The algorithm was executed against the PCORnet CDM at three institutions from January 1, 2009 to January 1, 2018, where a random selection of 50 cases and 50 noncases (individuals not meeting case criteria seen within the same calendar year and within 5 years of age of a case) were reviewed by a nephrologist, for a total of 150 cases and 150 noncases reviewed. The classification accuracy (sensitivity, specificity, positive and negative predictive value, F1 score) of the computable phenotype was determined. Results The algorithm identified a total of 2708 patients with nephrotic syndrome from 4,305,092 distinct patients in the CDM at all sites from 2009 to 2018. For all sites, the sensitivity, specificity, and area under the curve of the algorithm were 99% (95% CI, 97% to 99%), 79% (95% CI, 74% to 85%), and 0.9 (0.84 to 0.97), respectively. The most common causes of false positive classification were secondary FSGS (nine out of 39) and lupus nephritis (nine out of 39). Conclusion This computable phenotype had good classification in identifying both children and adults with primary nephrotic syndrome utilizing only ICD-9 and ICD-10 codes, which are available across institutions in the United States. This may facilitate future screening and enrollment for research studies and enable comparative effectiveness research. Further refinements to the algorithm including use of laboratory data or addition of natural language processing may help better distinguish primary and secondary causes of nephrotic syndrome.
Rationale and Trial Design of MesEnchymal Stem Cell Trial in Preventing Venous Stenosis of Hemodialysis Vascular Access Arteriovenous Fistula (MEST AVF Trial)
Piryani, Ameet K., Kilari, Sreenivasulu , Takahashi, Edwin A. , DeMartino, Randall R. , Mandrekar, Jay, Dietz, Allan B. , Misra, Sanjay , Takahashi, Edwin A , Misra, Sanjay , Dietz, Allan B , DeMartino, Randall R , Piryani, Ameet K., Kilari, Sreenivasulu , Mandrekar, Jay

Mayo Clinic

Kidney360 | September 27, 2021 | Volume: 2 | Issue: 12 | Pages: 1945-1952

10.34067/kid.0005182021 | PMID 35419530 Get It

Key Points At 1 year after placement, 60% of hemodialysis arteriovenous fistulas (AVF) will develop venous neointimal hyperplasia (VNH) and subsequent venous stenosis (VS). Autologous adipose-derived mesenchymal stem cells may help reduce VS formation associated with hemodialysis AVF. There are no therapies available to prevent VS formation associated with hemodialysis AVF. Background Hemodialysis arteriovenous fistulas (AVFs) are the preferred vascular access for patients on hemodialysis. In the Hemodialysis Fistula Maturation Study, 44% of the patients achieved unassisted maturation of their fistula without needing an intervention. Venous neointimal hyperplasia (VNH) and subsequent venous stenosis are responsible for lack of maturation. There are no therapies that can prevent VNH/VS formation. The goal of this paper is to present the background, rationale, and trial design of an innovative phase 1/2 clinical study that is investigating the safety of autologous adipose-derived mesenchymal stem cells delivered locally to the adventitia of newly created upper extremity radiocephalic (RCF) or brachiocephalic fistula (BCF). Methods The rationale and preclinical studies used to obtain a physician-sponsored investigational new drug trial are discussed. The trial design and end points are discussed. Results This is an ongoing trial that will complete this year. Conclusion This is a phase 1/2 single-center, randomized trial that will investigate the safety and efficacy of autologous AMSCs in promoting maturation in new upper-extremity AVFs. Clinical Trial registration number : NCT02808208
Elimination of Radiation-Induced Senescence in the Brain Tumor Microenvironment Attenuates Glioblastoma Recurrence
Fletcher-Sananikone, Eliot, Kanji, Suman, Tomimatsu, Nozomi, Cristofaro, Luis Fernando Macedo Di , Kollipara, Rahul K., Saha, Debabrata , Floyd, John R., Sung, Patrick, Hromas, Robert, Burns, Terry C., Kittler, Ralf , Habib, Amyn A., Mukherjee, Bipasha, Burma, Sandeep, Di Cristofaro, Luis Fernando Macedo , Fletcher-Sananikone, Eliot, Kanji, Suman, Tomimatsu, Nozomi, Kollipara, Rahul K., Saha, Debabrata , Floyd, John R., Sung, Patrick, Hromas, Robert, Burns, Terry C., Kittler, Ralf , Habib, Amyn A., Mukherjee, Bipasha, Burma, Sandeep

Mayo Clinic

Cancer Research | September 27, 2021 | Volume: 81 | Issue: 23 | Pages: 5935-5947

10.1158/0008-5472.can-21-0752 | PMID 34580063 Get It

Abstract Glioblastomas (GBM) are routinely treated with ionizing radiation (IR) but inevitably recur and develop therapy resistance. During treatment, the tissue surrounding tumors is also irradiated. IR potently induces senescence, and senescent stromal cells can promote the growth of neighboring tumor cells by secreting factors that create a senescence-associated secretory phenotype (SASP). Here, we carried out transcriptomic and tumorigenicity analyses in irradiated mouse brains to elucidate how radiotherapy-induced senescence of non-neoplastic brain cells promotes tumor growth. Following cranial irradiation, widespread senescence in the brain occurred, with the astrocytic population being particularly susceptible. Irradiated brains showed an altered transcriptomic profile characterized by upregulation of CDKN1A (p21), a key enforcer of senescence, and several SASP factors, including HGF, the ligand of the receptor tyrosine kinase (RTK) Met. Preirradiation of mouse brains increased Met-driven growth and invasiveness of orthotopically implanted glioma cells. Importantly, irradiated p21−/− mouse brains did not exhibit senescence and consequently failed to promote tumor growth. Senescent astrocytes secreted HGF to activate Met in glioma cells and to promote their migration and invasion in vitro, which could be blocked by HGF-neutralizing antibodies or the Met inhibitor crizotinib. Crizotinib also slowed the growth of glioma cells implanted in preirradiated brains. Treatment with the senolytic drug ABT-263 (navitoclax) selectively killed senescent astrocytes in vivo, significantly attenuating growth of glioma cells implanted in preirradiated brains. These results indicate that SASP factors in the irradiated tumor microenvironment drive GBM growth via RTK activation, underscoring the potential utility of adjuvant senolytic therapy for preventing GBM recurrence after radiotherapy. Significance: This study uncovers mechanisms by which radiotherapy can promote GBM recurrence by inducing senescence in non-neoplastic brain cells, suggesting that senolytic therapy can blunt recurrent GBM growth and aggressiveness.
Cardiovascular risk factors and cervical carotid plaque features on CT angiography
Benson, John C. , Nardi, Valentina , Brinjikji, Waleed , Benson, John , Nardi, Valentina , Hunt, Christopher H. , Lerman, Amir , Lanzino, Giuseppe

Mayo Clinic

The Neuroradiology Journal | September 27, 2021 | Volume: 35 | Issue: 3 | Pages: 346-351

10.1177/19714009211047450 | PMID 34569868 Get It

Background Little is known about the impact that cardiovascular (CV) risk factors have on the formation of various carotid atherosclerotic plaque features. This study set out to assess the association between CV risk factors and plaque characteristics on computed tomography (CT) angiography (CTA). Materials and methods A retrospective review was completed of consecutive patients that underwent a carotid endarterectomy and had CTA imaging of the head and neck vasculature. Atherosclerotic plaques of both carotid arteries were evaluated for calcification(s), low-density plaque (LDP) components, ulceration(s), and degree of stenosis. Various clinical CV risk factors were assessed using medical records. Last recorded laboratory levels were dichotomized into categories: total cholesterol <200 or ≥200 mg/dL, low-density lipoprotein (LDL) <130 or ≥130 mg/dL, high-density lipoprotein <35 or ≥35 mg/dL, and triglyceride <200 or ≥200 mg/dL. Results Of 97 included patients, 62 were male (63.9%); the average age was 72.7 (standard deviation = 9.5). Calcifications were in 95/97 (97.9%) of patients (one or both carotid plaques); LDP components were in 73/97 (75.3%), and ulcerations were in 21/97 (21.6%). Elevated total cholesterol and elevated LDL levels were both associated with a higher likelihood of LDP components ( p = 0.004 and p = 0.02, respectively). There were no other statistically significant associations between individual plaque features or severity of arterial stenosis and CV risk factors. Conclusion In carotid atherosclerotic plaques, LDP components are more frequently present in one or both carotid arteries in patients with elevated total cholesterol and/or LDL levels. Such findings raise the possibility that cholesterol levels may be directly related to the formation of specific high-risk plaque features.
Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases
Lin, Sinan , Mao, Ren , Qian, Chenchen , Wang, Jie , Bruining, David H. , Feagan, Brian G. , Chen, Minhu , Rieder, Florian , Rieder, Florian , Bettenworth, Dominik , Li, Jiannan , Jairath, Vipul

Mayo Clinic

Physiological Reviews | September 27, 2021 | Volume: 102 | Issue: 2 | Pages: 605-652

10.1152/physrev.00005.2021 | PMID 34569264 Get It

Intestinal fibrosis is considered an inevitable complication of Crohn’s disease (CD) that results in symptoms of obstruction and stricture formation. Endoscopic or surgical treatment is required to treat the majority of patients. Progress in the management of stricturing CD is hampered by the lack of effective antifibrotic therapy; however, this situation is likely to change because of recent advances in other fibrotic diseases of the lung, liver, and skin. In this review, we summarize data from randomized controlled trials (RCTs) of antifibrotic therapies in these conditions. Multiple compounds have been tested for antifibrotic effects in other organs. According to their mechanisms, they were categorized into growth factor modulators, inflammation modulators, 5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, intracellular enzymes and kinases, renin-angiotensin system (RAS) modulators, and others. From our review of the results from the clinical trials and discussion of their implications in the gastrointestinal tract, we have identified several molecular candidates that could serve as potential therapies for intestinal fibrosis in CD.
Effects of Intermittent Pneumatic Compression on Lower Limb Lymphedema in Patients with Type 2 Diabetes Mellitus: A Pilot Randomized Controlled Trial
Sire, Alessandro de , Inzitari, Maria Teresa , Moggio, Lucrezia , Sire, Giustino de, Supervía, Marta , Petraroli, Annalisa , Rubino, Mariangela , Carbotti, Delia Francesca, Succurro, Elena , Ammendolia, Antonio , Andreozzi, Francesco , de Sire, Alessandro , Succurro, Elena , Ammendolia, Antonio , Andreozzi, Francesco , Pinto, Monica

Mayo Clinic

Medicina | September 27, 2021 | Volume: 57 | Issue: 10 | Pages: 1018

10.3390/medicina57101018 | PMID 34684055 Get It

Background and Objectives: Diabetes mellitus type 2 (T2DM) is a chronic disease associated with fluid accumulation in the interstitial tissue. Manual lymphatic drainage (MLD) plays a role in reducing lymphoedema, like intermittent pneumatic compression (IPC). By the present pilot study, we aimed to evaluate the efficacy of a synergistic treatment with MLD and IPC in reducing lower limb lymphedema in T2DM patients. Materials and Methods: Adults with a clinical diagnosis of T2DM and lower limb lymphedema (stage II–IV) were recruited from July to December 2020. Study participants were randomized into two groups: experimental group, undergoing a 1-month rehabilitative program consisting of MLD and IPC (with a compression of 60 to 80 mmHg); control group, undergoing MLD and a sham IPC (with compression of <30 mmHg). The primary outcome was the lower limb lymphedema reduction, assessed by the circumferential method (CM). Secondary outcomes were: passive range of motion (pROM) of hip, knee, and ankle; quality of life; laboratory exams as fasting plasma glucose and HbA1c. At baseline (T0) and at the end of the 1-month rehabilitative treatment (T1), all the outcome measures were assessed, except for the Hb1Ac evaluated after three months. Results: Out of 66 T2DM patients recruited, only 30 respected the eligibility criteria and were randomly allocated into 2 groups: experimental group (n = 15; mean age: 54.2 ± 4.9 years) and control group (n = 15; mean age: 54.0 ± 5.5 years). At the intra-group analysis, the experimental group showed a statistically significant improvement of all outcome measures (p < 0.05). The between-group analysis showed a statistically significant improvement in pROM of the hip, knee, ankle, EQ-VAS, and EQ5D3L index at T1. Conclusions: A multimodal approach consisting of IPC and MLD showed to play a role in reducing lower limb lymphedema, with an increase of pROM and HRQoL. Since these are preliminary data, further studies are needed.
Machine Learning Consensus Clustering Approach for Hospitalized Patients with Phosphate Derangements
Dumancas, Carissa , Nissaisorakarn, Voravech , Keddis, Mira T. , Kattah, Andrea G. , Pattharanitima, Pattharawin , Petnak, Tananchai , Vallabhajosyula, Saraschandra , Mao, Michael A. , Erickson, Stephen B., Cheungpasitporn, Wisit , Dumancas, Carissa Y, Nissaisorakarn, Voravech , Pattharanitima, Pattharawin , Petnak, Tananchai , Vallabhajosyula, Saraschandra , Mao, Michael A , Dillon, John J, Cheungpasitporn, Wisit , Thongprayoon, Charat , Garovic, Vesna D. , Dillon, John

Mayo Clinic

Journal of Clinical Medicine | September 27, 2021 | Volume: 10 | Issue: 19 | Pages: 4441

10.3390/jcm10194441 | PMID 34640457 Get It

Background: The goal of this study was to categorize patients with abnormal serum phosphate upon hospital admission into distinct clusters utilizing an unsupervised machine learning approach, and to assess the mortality risk associated with these clusters. Methods: We utilized the consensus clustering approach on demographic information, comorbidities, principal diagnoses, and laboratory data of hypophosphatemia (serum phosphate ≤ 2.4 mg/dL) and hyperphosphatemia cohorts (serum phosphate ≥ 4.6 mg/dL). The standardized mean difference was applied to determine each cluster’s key features. We assessed the association of the clusters with mortality. Results: In the hypophosphatemia cohort (n = 3113), the consensus cluster analysis identified two clusters. The key features of patients in Cluster 2, compared with Cluster 1, included: older age; a higher comorbidity burden, particularly hypertension; diabetes mellitus; coronary artery disease; lower eGFR; and more acute kidney injury (AKI) at admission. Cluster 2 had a comparable hospital mortality (3.7% vs. 2.9%; p = 0.17), but a higher one-year mortality (26.8% vs. 14.0%; p < 0.001), and five-year mortality (20.2% vs. 44.3%; p < 0.001), compared to Cluster 1. In the hyperphosphatemia cohort (n = 7252), the analysis identified two clusters. The key features of patients in Cluster 2, compared with Cluster 1, included: older age; more primary admission for kidney disease; more history of hypertension; more end-stage kidney disease; more AKI at admission; and higher admission potassium, magnesium, and phosphate. Cluster 2 had a higher hospital (8.9% vs. 2.4%; p < 0.001) one-year mortality (32.9% vs. 14.8%; p < 0.001), and five-year mortality (24.5% vs. 51.1%; p < 0.001), compared with Cluster 1. Conclusion: Our cluster analysis classified clinically distinct phenotypes with different mortality risks among hospitalized patients with serum phosphate derangements. Age, comorbidities, and kidney function were the key features that differentiated the phenotypes.